This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone quarter ended 30 Sep 2026: revenue down 23%, loss narrowed to Rs 15.89 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
By the next day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.9 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the standalone quarter ended 30 September 2026, revenue was Rs 531.98 lakh, down 22.6% from Rs 687.15 lakh, while net loss was Rs 15.89 lakh versus Rs 43.95 lakh a year earlier. EBITDA margin improved to 7.97% from 2.70%. Standalone half year to 30 September 2026: revenue Rs 951.67 lakh, net loss Rs 74.26 lakh and operating cash flow negative Rs 95.71 lakh. Borrowings were 2.57 times equity. Limited review: unqualified.
Revenue fell and losses persisted despite a narrower quarterly loss and better EBITDA margin. High debt and negative cash flow add risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.32 Cr | ₹6.87 Cr | −22.6% |
| Operating profit | −₹0.23 Cr | −₹0.44 Cr | loss narrowed |
| Profit after tax | −₹0.16 Cr | −₹0.44 Cr | loss narrowed |
| EBITDA margin | 8.0% | 2.7% | +5.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.